PERCUTANEOUS MODIFICATION OF VASCULAR EXTRACELLULAR MATRIX TO PREVENT AND TREAT VASCULAR RESTENOSIS
20180056086 ยท 2018-03-01
Inventors
Cpc classification
A61N5/062
HUMAN NECESSITIES
A61M2025/105
HUMAN NECESSITIES
A61N2005/063
HUMAN NECESSITIES
A61L29/16
HUMAN NECESSITIES
A61B2017/22051
HUMAN NECESSITIES
A61N2005/0643
HUMAN NECESSITIES
A61L29/14
HUMAN NECESSITIES
International classification
A61B17/22
HUMAN NECESSITIES
Abstract
Aspects of disclosed embodiments relate to systems, devices and methods for treating and preventing restenosis by cross-linking collagen fibrils of the vessel wall at the intervention site. The devices described are drug-eluting devices comprising: an expandable member or a balloon; a cross-linking agent; and a photoactivating light source. Upon the inflation of the expandable member or the balloon the cross linking agent is released and photoactivated in a therapeutically effective amount for cross-linking collagen fibrils.
Claims
1. A device comprising: an expandable member having a distal end, a proximal end and a working length therebetween; a cross-linking agent; and a photoactivating light source.
2. The device of claim 1, wherein the expandable member is a balloon.
3. The device of claim 1, wherein the expandable member is coated with a layer comprising a carrying agent.
4-5. (canceled)
6. The device of claim 1, wherein the cross-linking agent is supplied through a catheter of the device.
7. The device of claim 1, wherein the photoactivating light source is supplied by and/or incorporated on the expandable member.
8-9. (canceled)
10. The device of claim 1, wherein in operable position, the cross-linking agent induces cross-linking of collagen fibrils responsive to photoactivating light incident on the cross-linking agent.
11. The device of claim 1, wherein the cross linking agent comprises one or more photoactive bioflavonoids selected from the group consisting of: proanthocyanidin, catechin, epicatechin, epigallo catechin, epicatechin gallate, epigallocatechin gallate, quercetin, tannic acid, and any combination thereof.
12. The device of claim 1, wherein the cross-linking agent comprises one or more photoactive substances.
13. The device of claim 10, wherein the cross-linking agent comprises riboflavin.
14-15. (canceled)
16. The device of claim 1, wherein the photoactivating light is ultraviolet (UV) light.
17. The device of claim 1, wherein the photoactivating light has a wavelength within the range of 300-500 nm.
18. (canceled)
19. The device of claim 1, wherein the photoactivating light is produced by a LED device.
20. The device of claim 1, wherein the source is an external source of electromagnetic radiation.
21. The device of claim 1, wherein the photoactivating light source is external and uses a waveguide for its delivery.
22. (canceled)
23. The device of claim 1, wherein the photoactivating light source is a vascular catheter comprising a LED device.
24. The device of claim 1, wherein the photoactivating light source is a vascular catheter operative to allow the passage of an optical fiber able to convey a laser radiation.
25. (canceled)
26. The device of claim 1, wherein the cross-linking agent is released in a therapeutically effective amount at an intervention site (in-situ).
27. (canceled)
28. The device of claim 26, wherein 30 seconds post initial expansion of the expandable member more than 80% of cross-linking agent is released from the expandable member surface into the surface of the intervention site.
29-30. (canceled)
31. A method of delivering a cross-linking composition to a vessel wall of a body lumen, wherein the vessel wall comprises collagen, comprising the steps of: providing an expandable member having a distal end, a proximal end and a working length therebetween; cross-linking agent; and a photoactivating light source; positioning the expandable member within an intervention site of a body lumen; expanding the expandable member and releasing intraluminally the cross-linking agent onto the vessel wall; and photoactivating the cross-linking agent, for cross-linking a collagen fibrils of the vessel wall.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Exemplary embodiments are illustrated in referenced figures. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown to scale. The figures are listed below.
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
DETAILED DESCRIPTION
[0038] The present invention provides devices, systems and methods useful for treating and/or preventing restenosis. According to an embodiment, restenosis is treated and/or prevented by changing a property of the extracellular matrix (ECM) within a tissue surrounding a vascular stent or atherosclerotic lesion. According to an embodiment, treating, decreasing, ameliorating, and/or preventing restenosis is achieved by cross linking a collagen fibril of the ECM. According to an embodiment, cross linking is induced (e.g., catalyzed) by a photosensitizer agent which is photoactivated by a light source in order to cross-link collagen of the ECM. In one embodiment, cross linking a collagen fibril of the extracellular matrix decrease the risk of distal embolization using stent delivery or angioplasty.
[0039] It is noted that the terms collagen and collagen fibril as used herein can be used interchangeably.
[0040] Throughout the text the terms vessel and blood vessel are used interchangeably and refer to a blood vessel of interest for the intervention procedure. In one embodiment, the blood vessel is a coronary blood vessel. In one embodiment, the blood vessel is an artery. In one embodiment, the blood vessel is a coronary artery. In one embodiment, the blood vessel is a blood vessel in proximity to a coronary artery. In one embodiment, the blood vessel is a peripheral blood vessel. In one embodiment, the blood vessel is a renal artery. In one embodiment, the blood vessel is a venous graft. In one embodiment, a blood vessel is an arterial graft. In one embodiment, a blood vessel is a vein. In one embodiment, the intervention site is the site wherein the intervention procedure for the prevention and/or treatment of restenosis is carried out.
[0041] It should be noted that the term light as used herein may refer to electromagnetic radiation of any suitable wavelength for the purposes of the applications disclosed herein. Accordingly, the term light should not be construed as being limited to visible light and may additionally or alternatively include non-visible radiation such as, for example, laser light in the infrared range and UV light.
[0042] Disclosed herein is a device comprising: an expandable member having a distal end, a proximal end and a working length there between; an active agent (e.g., a cross-linking agent); and a photoactivating light source operative to emit light for activating, when in an operable position, the active agent. Optionally, when the expandable member and the photoactivating light source are in operable position, the cross-linking agent cross-links or catalyzes the cross linking of a collagen surrounding the expandable member. In some embodiments, there is provided a system comprising a device as described herein and a power source for actuating the photoactivating light source and/or the expansion (e.g., inflation) of the expandable member.
[0043] Optionally, the device comprises a cross linking agent-eluting expandable member, wherein the expandable member includes the photoactivating light source. Optionally, the device comprises the cross linking agent-eluting expandable member, wherein the photoactivating light source may be embedded within the expandable member. In one embodiment, the device comprises a cross linking agent-eluting balloon, wherein the photoactivating light source may be placed on an outer surface of the expandable/inflatable balloon. Optionally, the photoactivating light source may be placed on at least a portion of an outer surface of the inflatable balloon. It is noted that the terms inflatable and expandable as used herein can be used interchangeably.
[0044] Optionally, the expandable member is a balloon. Optionally, the expandable member is made of a deformable and/or an expandable latex, plastic or rubber.
[0045] The expandable member (e.g., balloon) may be made of a wide variety of materials including, for example, polytetrafluoroethylenes (Teflon), polyethylenes, (e.g., high density polyethylenes), polyethylene terephthalate (PET), polypropylenes, polyurethanes, nylons including nylon 6 and nylon 12, polyesters including polyalkylene terephthalate polymers and copolymers, (e.g., thermoplastic polyester elastomers such as Hytrel, which is a block copolymer containing a hard polybutylene terephthalate segment and soft amorphous segments based on long-chain polyether glycols), polyimides, polyamides including polyether-block-co-polyamide polymers (e.g., Pebax), and the like. These materials may also be blended or provided in a composite or multi-layer construction. Typically, PET balloons are substantially optically clear and permit the transmission of light over a broad spectrum.
[0046] Optionally, the expandable member size ranges from 2 to 25 millimeter (mm) in diameter, or alternatively 4 to 12 mm in diameter, or alternatively 2 to 4 mm in diameter. Optionally, the expandable member size ranges from 8 to 40 mm in length, or alternatively 20 to 100 mm in length. Optionally, the expandable member is rated for a pressure capability of 5 to 20 atmospheres (ATM), or alternatively 8 to 20 ATM, or alternatively 10 to 20 ATM or alternatively 5 to 15 ATM. Each possibility represents a separate embodiment of the present invention. The different embodiments can be combined at will.
[0047] Optionally, the active agent (e.g., cross-linking agent) is a photoactivatable substance. Optionally, the photoactivating light source may activate the active agent in situ. Alternatively, the photoactivating light source may activate the active agent within a blood vessel and/or a vascular tissue. Alternatively, the photoactivating light source may activate the active agent upon release within a blood vessel.
[0048] In a non-limiting example, the active agent is a cross-linking agent. In a non-limiting example, the cross-linking agent is capable of cross linking an organic molecule. In a non-limiting example, the cross-linking agent is capable of cross linking a protein. In a non-limiting example, the cross-linking agent is capable of cross linking a structural protein. In a non-limiting example, the cross-linking agent is capable of cross linking a connective tissue structural protein. Alternatively, the cross-linking agent is a photosenitizer. Typically, the photosenitizer doesn't form a chemical interaction with the ECM. The term photosensitizer as used herein, refers to an agent that is capable of absorbing light energy (e.g., from the photoactivating light source) and deliver, as a result of the light absorption, energy to catalyze a chemical reaction.
[0049] In a non-limiting example, the cross-linking agent may include one or more photoactive bioflavonoids selected from the group consisting of proanthocyanidin, catechin, epicatechin, epigallo catechin, epicatechin gallate, epigallocatechin gallate, quercetin, tannic acid, and any combination thereof. In another non-limiting example, the cross-linking agent comprises one or more photoactive substances. In yet another non-limiting example, the cross-linking agent comprises a photoactive substance that comprises riboflavin.
[0050] In another non-limiting example, the cross-linking agent comprises an enzyme capable of cross-linking collagen fibers. In a non-limiting example, lysyl oxidase is used to cross-link collagen fibers. In another non-limiting example, the cross-linking agent comprises: carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA) or combinations thereof.
[0051] Optionally, the device further comprises an agent capable of preventing collagen degradation. In a non-limiting example, the agent capable of preventing collagen degradation is a metalloproteinase inhibitor. Optionally, the agent capable of preventing collagen degradation (e.g., metalloproteinase inhibitor) is released along with the cross-linking agent.
[0052] Optionally, the cross-linking agent may induce cross-linking of a collagen fibril at the intervention site, following a photoactivating light incident on the cross-linking agent. Optionally, the photoactivating light initiates the cross-linking activity by irradiating the applied cross-linking agent (via the release of reactive oxygen radicals). Optionally, the cross-linking agent acts as a sensitizer to convert O.sub.2 into singlet oxygen which causes cross-linking of collagen within a biological tissue. In a non-limiting example, the biological tissue is a biological tissue comprising of collagen fibrils selected from: a venous tissue, a cardiac valvular tissue, a connective tissue, a vascular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia a tissue of a muscular aponeurosis or an extracellular matrix tissue. In one embodiment, the biological tissue is the extracellular matrix.
[0053] Optionally, the device further includes a carrying agent. As used herein, the carrying agent is any mixture of inert materials which will deliver or release the active agent, the metalloproteinase inhibitor and/or the cross linking agent in situ and in a desired elution profile. Optionally, the carrying agent provides a predefined release profile of the cross linking agent. Optionally, the carrying agent glues or adheres the active agent, the metalloproteinase inhibitor and/or cross linking agent to the expandable member. In a non-limiting example, carrying agent is a polymer. In one embodiment, carrying agent is a resin. In another non-limiting example, the carrying agent is biologically inert.
[0054] Optionally, the photoactivating light is ultraviolet (UV) light. In one embodiment, the photoactivating light has a wavelength within the range of 10 to 500 nm, 10 to 400 nm, or 300 to 500 nm. Each possibility represents a separate embodiment of the present application. The different embodiments can be combined at will. In one embodiment, the photoactivating light has a wavelength within the range of 450 to 480 nm.
[0055] Optionally, the photoactivating light is a radiation produced by a laser device. In one embodiment, the photoactivating light is a radiation produced by a light emitting diode (LED) device. Optionally, the photoactivating light source is an external source of electromagnetic radiation. In one embodiment, the external source of electromagnetic radiation is a vascular catheter with LED device operatively coupled thereto. Optionally, the external source of electromagnetic radiation is a vascular catheter operative to allow also the passage of an optical fiber able to convey a laser radiation.
[0056] Optionally, the photoactivating light source can be embedded in the distal end, proximal end or working length of the expandable member. In one embodiment, the photoactivating light source is located within the expandable member. Optionally, the photoactivating light source covers at least a portion of the expandable member. In one embodiment, the LED is located within the expandable member.
[0057] Optionally, the device is a tubular vascular implant. Optionally, the expandable member acquires an expanded configuration at the intervention site only.
[0058] Throughout the following description, similar elements of different embodiments of the device are referenced by element numbers differing by integer multiples of 100. For example, expandable member of
[0059] Reference is now made to
[0060] Optionally, active agent 110 overlays, at least partially, expandable member 102. Optionally, photoactivating light source 112 is located within expandable member 102, such as on a central longitudinal axis Z that runs along a length of expandable member 102 from proximal end 104 to distal end 106.
[0061] Reference is now made to
[0062] Reference is now made to
[0063] For a non-limiting example, expandable member 302 may be formed, at least partially, of a porous material. In another non-limiting example, expandable member 302 may be formed, at least partially, of a porous material which provides release sites 316 and is formed therein one or more release sites 316. Optionally, active agent 312 is embedded in layers 314 coating expandable member 302. Optionally, active agent 312 is embedded in a section of layers 314 coating working length 308 of expandable member 302. Optionally, release sites 316 are arranged along a portion of working length 308, such that active agent 310 is released through release sites 316. Optionally, release sites 316 of expandable member 302 are in the form of reservoirs containing active agent 310 for release.
[0064] Reference is now made to
[0065] Reference is now made to
[0066] Reference is now made to
[0067] Reference is now made to
[0068] Reference is now made to
[0069] Reference is now made to
[0070] According to another aspect, the invention provides a method for treating and/or preventing restenosis. Optionally, the invention provides a method of delivering a cross-linking agent to a vessel wall of body lumen (such as of a blood vessel), wherein the vessel wall comprises collagen.
[0071] Reference is now made to
[0072] An expandable member of the device is positioned within an intervention site of a body lumen (such as of a blood vessel) (Step 1052). The expandable member is expended (Step 1054). Optionally, an expandable member surrounds a portion of the catheter near or at a distal end of the catheter and the catheter is operatively coupled with an expansion mechanism for expanding the expandable member. For example, the catheter may comprise a tube operative to provide inflation fluid for inflating a balloon. In an alternative embodiment, the expandable member/inflatable balloon releases the catheter at the intervention site and for expanding (e.g., through inflation) the expandable member to a predetermined size.
[0073] The cross-linking agent is released intraluminally on to the vessel wall (Step 1056). Optionally, the cross-linking agent is released in a therapeutically effective amount at an intervention site. Optionally, the cross-linking agent is released in a therapeutically effective amount upon inflation/expansion of the expandable member. Optionally, the release of a therapeutically effective amount of cross-linking chemical occurs in between 1 second and 40 seconds. Optionally, the release occurs in between 1 second and 20 seconds. Optionally, the release occurs in between 1 second and 10 seconds. Optionally, the intervention site is within a blood vessel. Optionally, the release of a therapeutically effective amount of cross-linking chemical is triggered by expansion of the expandable member into an expanded configuration. Optionally, 30 seconds post initial expansion (e.g., inflation) of the expandable member, more than 80% of cross-linking agent is released from the expandable member surface into the surface of the intervention site. Optionally, more than 40%, more than 50%, more than 60%, or more than 70% of the cross-linking agent is released from the expandable member surface within 30 seconds from expansion of the expandable member. Alternatively, the cross linking agent coating the expandable member may be pressed against the vessel wall upon expansion of the expandable member.
[0074] The photoactivating light source is operated to photoactivate the cross-linking agent, thus cross-linking a collagen fibril (Step 1058).
[0075] Optionally, the photoactivating light source is supplied by a catheter, wherein the catheter is inserted into a vessel. Alternatively, the light source may be supplied close to a vessel wall, e.g., by the cavity of the expandable member.
[0076] Optionally, irradiation for photoactivation occurs immediately with the release of the cross-linking agent at the intervention site. Optionally, irradiation for photoactivation is concomitantly performed while expanding of the expandable member into expanded configuration. Optionally, photoactivation by the light source is effected responsive to irradiating the cross-linking agent with a single pulse having a duration of, e.g., 4 to 60 seconds, 4 to 20 seconds, 20 to 60 seconds, or 10 to 30 seconds. Optionally, photoactivation by the light source is effected responsive to irradiating the cross-linking agent with a series of multiple pulses over a duration of, e.g., 4 to 60 seconds, 4 to 20 seconds, 20 to 60 seconds, or 10 to 30 seconds. Optionally, each photoactivation pulse lasts from e.g., 1 Pico second to 5 seconds, from 1 Pico second to 1 millisecond, from 1 millisecond second to 1 second, or from 1 second to 10 seconds. Each possibility represent a separate embodiment of the present invention.
[0077] Optionally, the activated cross-linking agent is used for cross-linking a collagen fibril. In one embodiment, collagen is any one of type I to XXVIII collagen. In one embodiment, collagen fibrils compose part of the extracellular matrix (ECM). Optionally, cross-linking collagen fibrils change the permeability of the ECM.
[0078] Optionally, after using the device to cross-link collagen fibrils of the ECM, the device is withdrawn and a vascular (e.g., BMS or DES) stent may be delivered.
[0079] In the discussion unless otherwise stated, adjectives such as substantially and about modifying a condition or relationship characteristic of a feature or features of an embodiment of the invention, are understood to mean that the condition or characteristic is defined to within tolerances that are acceptable for operation of the embodiment for an application for which it is intended.
[0080] Unless otherwise indicated, the word or in the specification and claims is considered to be the inclusive or rather than the exclusive or, and indicates at least one of, or any combination of items it conjoins.
[0081] In the description and claims of the present application, each of the verbs, comprise, include and have and conjugates thereof, are used to indicate that the object or objects of the verb are not necessarily a complete listing of components, elements or parts of the subject or subjects of the verb.
[0082] Descriptions of embodiments of the invention in the present application are provided by way of example and are not intended to limit the scope of the invention. The described embodiments comprise different features, not all of which are required in all embodiments of the invention. Some embodiments utilize only some of the features or possible combinations of the features. Variations of embodiments of the invention that are described, and embodiments of the invention comprising different combinations of features noted in the described embodiments, will occur to persons of the art.